Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) have generated billions of dollars from their coronavirus vaccines. That was as governments raced to get their populations vaccinated. Today, about 67% of the U.S. population is fully vaccinated.

But vaccine revenue is far from over for these vaccine leaders. That's because the world now is in need of booster shots. Moderna and Pfizer both have asked the U.S. Food and Drug Administration (FDA) to authorize their omicron-specific boosters for the fall vaccination season. So, which stock is the best bet as we head into this new phase? Let's find out.

Moderna was among the first to talk about its work on an omicron-specific booster. And the company was the first to share positive data from its clinical trials. Earlier this summer, Moderna said its booster candidate even was effective against omicron subvariants BA.4 and BA.5.

Continue reading

Source Fool.com